




CEE Equity Research | Hungary | Real Estate 27 February 2019

Duna House

Recommendation: Buy

Target price (12M): Under revision

Hun. Core HUF million	2018 Q4	2017 Q4	Ch (%)
Revenues	2,142	1,229	+74%
EBITDA	387	238	+63%
EBIT	360	218	+65%
Profit	256	173	+48%
EPS	74	50	+485
Cummulated EPS	502	272	+184%
P/E	8x	10x	
No. of transactions (ths)	34	33	+2%



Share price close as of 27/02/2019	HUF 4,000	Bloomberg	DUNAHHOUS HB
Number of shares [million]	3,5	Reuters	DUNAHOUSE.BU
Market capitalization [HUF mn/EUR mn]	12,856 / 37	Free float	30%
Daily turnover 12M [EUR th]	1.46	52 week range	HUF 3,450-4,600

Strong outlook, finally a turnaround in Poland and generous dividend!

Equity Analyst Gellert Gaal +361 489 2228 g.gaal@con.hu

50 Alkotás Street, Budapest www.con.hu In short: Duna House posted a strong quarterly results with which the company has reached a profit of HUF 1.7 bn (EPS 502). With this amount DH has met its FY profit guidance. What is more, management gave strong profit outlook of HUF 2.3 bn (EPS 690) made up of HUF 1.25 bn from Core Operation and HUF 1.05 bn from Development. Last but not least, Board of Directors will propose DPS of HUF 250 to ordinary shares (6.25% on today's closing price).

Our takeaway from the 2019 guidance is the followings:

 Management expects ca. HUF 1,175 million from Hungarian core operation, which seems relatively strong given the missing LTP segment. Basically they believe that growth will compensate the missing income from LTP segment.



- Improving Polish operation (supported by the latest acquisition) will add growth to bottom-line in an extent of HUF 75 million.
- Management expects robust loan reimbursement to continue in the tune of 20 - 30%
- House prices are expected to climb by 5-10% coupled with 160-180k transactions.

Q4 profit and H1 results are expected to be muted due to the transaction costs of transactions of Gold Finance. Excluding these cost incurred in Q4 and the non-recurring items throughout the year, profit excluding development should have arrived to HUF 1.26 bn ca. 7% higher vs. HUF 1.18 bn the actual number.

Financials: Operation-wise, the last quarter was subdued as the new polish entity (Gold Finance) was consolidated, reaching 17% EBIT margin only, while in absolute term managed to grow significantly from HUF 218 m to 360 m (+65% y-o-y). As far as dividend concerned, DH proposes HUF 250 DPS ca. HUF 850 million implying a little higher pay-out 56% vs. avg. of 47% in the recent years from adjusted profit as the developments have contributed nicely in 2018 and expected to add significant sums in 2019 as well.

On the country breakdown, Polish operation remained in the red throughout the year (- HUF 56 million), but pushing significantly down on the back of the above mentioned one time transaction costs. The profit of united entity is expected to be climb to ca. HUF 75 million in 2019. This improvement should come from the lack of transaction costs, severance costs, and from synergies. Since management expects ca. HUF 75 million profit from Polish operation, which should be materialize only in H2, the normalized FY profit should be in the range HUF 100 – 150 million, in our view which should be ca. 10 – 12% of the profit of Hungarian operation.


Core operation:

- Financial intermediary: The segment has performed weak this quarter due to 1), decelerating loan origination in Hungary (+15% in Q4 vs. 40% Q1-3); 2) the consolidation of Gold Finance in Poland. EBIT margin has fallen to 18% vs. 27% last year. Management noted that, cost optimization has already commenced which will have a positive effect only in H2 due to severance cost. Moreover, they expect improving profitability due to synergies and better bargaining power at banks as they become a sizeable player in the polish market, resulting in higher commissions.
- Franchise segment improved significantly thanks to better volumes and some optimisation steps. Management provided a



positive outlook for new office opening both in Hungary and in Poland. Quarterly segment EBIT margin climbed to 17% from 9% on a yearly comparison.

 Own Offices temporarily turned red on the back of elevated indirect cost.



Source: Company reports

Transaction numbers came slightly higher (+3% y-o-y) in 2018 compared to 2017. We are in a view that the latest gov's measure to further support families should add impetus to transaction numbers but only after July when it comes to force. Until then, participants may await until the middle of the year to benefit from the new program deferring their purchase. Thus, a moderation in numbers could be expected in H1 which should not necessarily explained by slowing macro, in our view.

Developments:

- DH reached better than expected results on the Reviczky project, only one flat is remained to be sold.
- Plans to start the second phase of Forest Hill called Panorama as it will be subjected to 5% VAT. The project has unique, and exclusive characteristics thus it is expected to target high end customers. Based on the assumptions below we expect ca. HUF 180 - 200 per share value additions from this project.
- Last but not least, completion of the first phase of Forest Hill is delayed due to labour shortage to after 2019 Q2 (originally expected in 2019 Q1).
 Roughly 70% of the flats are already sold.
- MyCity Residence project is well on track, 71% of the flats are sold and the construction was commenced in January, and expected to be completed by the end of October.

Opinion: This quarterly result was full of information, mainly positive, in our view. We are definitely happy for the strong guidance for 2019 and for the generous



dividend. With the proposed DPS DH has ca. 6.3% dividend yield one of the highest in the Budapest Stock Exchange. We also welcome forecasted operational improvements in Poland as the operation should make a turnaround from red (HUF -56 million) to black (HUF 75 million) in this year based on management expectations.

We expect positive share price reaction mainly due to the nice DPS proposal. Also we will incorporate the new guidance and operational KPI's into our earnings model, and release an update soon.

Quarterly P&L

	Q4 2018	Q4 2017	Ch (%)
Revenue	2,142	1,229	74%
Operating revenue	2,006	1,195	68%
Other income	136	33	311%
OPEX	1,783	1,011	76%
Cost of materials	18	19	-3%
Cost of sold goods and services	355	241	47%
Used services	1,145	1,285	-11%
Personnel expenses	194	154	26%
Depreciation and amortization	28	20	38%
Other operating expenses	43	-708	-106%
EBITDA	387	238	63%
EBIT	360	218	65%
Financial income	6	9	-29%
Financial expense	35	21	71%
Revaluation	12	1	1900%
EBT	319	206	55%
Income tax expense	-63	-33	91%
Net income	256	173	48%
Transaction Number	34,443	33,853	2%
Intermediated loans [HUF m]	34,428	18,807	83%
EPS	74	50	48%
EBIT margin	17%	18%	

Source: company reports



Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts certification and other important disclosures, please refer to the "Disclaimer" section at the end of this report.

DISCLAIMER 1.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country's jurisdiction. For important disclosures to U.S. investors, please refer of the "Notice to U.S. Investors" section at the end of this Disclaimer.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm's capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients' behalf in strict compliance with the Hungarian Capital Markets Act.

ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts' compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter's exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.



EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if covering analyst considers new information may change the valuation materially and if this may take more time.
Coverage in transition	Coverage in transition rating is assigned to a stock if there is a change in analyst.

Securities prices:

Prices are taken as of the previous day's close on the home market unless otherwise stated.

Valuations and risks:

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at Rating Methodology on our website. (https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038)

Research disclosures:

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at Rating history. (https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038)

GENERAL

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

NOTICE TO US INVESTORS

This report was prepared, approved, published and distributed Concorde Securities Ltd. located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by LXM LLP USA, a U.S. registered broker dealer, on behalf of Concorde Securities Ltd. only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through LXM LLP USA.

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.



Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Concorde Securities Ltd. is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Concorde Securities Ltd. solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by LXM LLP USA and elsewhere in the world by Concorde Securities Ltd. or an authorized affiliate Concorde Securities Ltd. This document does not constitute an offer of, or an invitation by or on behalf of Concorde Securities Ltd. or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Concorde Securities Ltd. or its Affiliates consider to be reliable. None of Concorde Securities Ltd. accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

LXM LLP USA assumes responsibility for the research reports content in regards to research distributed in the U.S. LXM LLP USA or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. LXM LLP USA has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of LXM LLP USA at the time of the publication of this research report. As of the publication of this report LXM LLP USA, does not make a market in the subject securities.

DISCLAIMER 2.

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.